SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating ChemoCentryx, Inc. Buyout

Wilmington, Delaware--(Newsfile Corp. - August 4, 2022) - Rigrodsky Law, P.A. is investigating ChemoCentryx, Inc. ("ChemoCentryx") (NASDAQ: CCXI) regarding possible breaches of fiduciary duties and other violations of law related to ChemoCentryx's agreement to be acquired by Amgen. Under the terms of the agreement, ChemoCentryx's shareholders will receive $52.00 per share.

To learn more about this investigation and your rights, visit:

To contact Seth D. Rigrodsky or Gina M. Serra cost free, call or text (302) 295-5310 or email

Rigrodsky Law, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities fraud and corporate class actions nationwide.

Attorney advertising. Prior results do not guarantee a similar outcome.

Rigrodsky Law, P.A.
Seth D. Rigrodsky, Esq.
Gina M. Serra, Esq.
Call or Text: (302) 295-5310

To view the source version of this press release, please visit